Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease
2019-003399-38Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), arteriosclerosis obliterans and intermittent claudication (IC) comparing Semaglutide 1 mg once-weekly with Placebo once-weekly (2 arms). Primary endpoint: Change in maximum walking distance on a constant load treadmill test. Started Jun 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)arteriosclerosis obliteransintermittent claudication (IC)
Beyond the preview
Go deeper on 2019-003399-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003399-38.